VHCP Management, LLC 13F 持仓 · 最近申报 2016年Q4
VHCP Management 在 2016年Q4（报告期截至 2016-12-31）的 SEC 13F 申报中报告了 21 只证券，申报市值合计 9,299.90 万美元。前几大持仓：DBVTF（33.47%）、HRTX（15.43%）、CHRS（9.25%）。本季前 25 大持仓中：新建仓 1 只、增持 2 只、清仓 4 只。
| 排名 | 代码 | 公司 | 市值 | 占组合 | 股数 | 变动 |
|---|---|---|---|---|---|---|
| 1 | DBVTF | DBV Technologies | $31.1M | 33.47% | 456,893 | 持平 |
| 2 | HRTX | Heron Therapeutics Inc | $14.4M | 15.43% | 1.1M | 持平 |
| 3 | CHRS | Coherus Biosciences Inc | $8.6M | 9.25% | 305,505 | 持平 |
| 4 | BCRX | BioCryst Pharmaceuticals Inc | $7.3M | 7.86% | 1.2M | 增持 |
| 5 | AVDL | Avadel Pharmaceuticals | $5.2M | 5.59% | 500,000 | 持平 |
| 6 | RARX | Ra Pharmaceuticals | $3.5M | 3.80% | 232,500 | 新建仓 |
| 7 | ADVM | Adverum Biotechnologies | $3.2M | 3.44% | 1.1M | 持平 |
| 8 | LPCN | Lipocine Inc | $3.1M | 3.36% | 849,921 | 持平 |
| 9 | CLCD | CoLucid Pharmaceuticals | $2.5M | 2.67% | 68,190 | 持平 |
| 10 | SIOX | Axovant Sciences Ltd | $2.3M | 2.46% | 184,110 | 持平 |
| 11 | OCRX | Ocera Therapeutics | $1.9M | 2.06% | 912,050 | 增持 |
| 12 | ASND | Ascendis Pharma A/S | $1.8M | 1.96% | 90,000 | 持平 |
| 13 | PDSB | Edge Therapeutics Inc | $1.7M | 1.82% | 135,000 | 持平 |
| 14 | STML | Stemline Therapeutics Inc | $1.4M | 1.56% | 135,420 | 持平 |
| 15 | ARCT | Alcobra Ltd | $1.4M | 1.49% | 658,910 | 持平 |
| 16 | ABIO | ARCA biopharma Inc | $1.3M | 1.42% | 462,399 | 持平 |
| 17 | AKTX | Akari Therapeutics Plc | $1.1M | 1.20% | 158,352 | 持平 |
| 18 | CTMX | CytomX Therapeutics Inc | $706,000 | 0.76% | 64,200 | 持平 |
| 19 | BOLD1 | Audentes Therapeutics | $274,000 | 0.29% | 15,000 | 持平 |
| 20 | SRRA | ProNAI Therapeutics Inc | $84,000 | 0.09% | 56,056 | 持平 |
| 21 | AGLE | Aeglea BioTherapeutics | $26,000 | 0.03% | 6,000 | 持平 |
| 22 | ACHN | Achillion Pharmaceuticals Inc | $0 | 0.00% | 0 | 清仓 |
| 23 | LRMR | Zafgen Inc | $0 | 0.00% | 0 | 清仓 |
| 24 | ONC | BeiGene Ltd | $0 | 0.00% | 0 | 清仓 |
| 25 | RGNX | REGENXBIO Inc | $0 | 0.00% | 0 | 清仓 |
来源：SEC 13F 申报文件 · 截至 2016-12-31
本期 13F-HR 中的全部持仓，以及相对上季度的变化。
13F 持仓，最新季度
来源SEC EDGAR13F-HR